{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:23:38Z","timestamp":1761920618285},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T00:00:00Z","timestamp":1565654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T00:00:00Z","timestamp":1565654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s12029-019-00293-y","type":"journal-article","created":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T04:28:33Z","timestamp":1565670513000},"page":"584-590","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Extrahepatic Malignancies After Treatment with Direct Antiviral Agents for Chronic HCV Infection"],"prefix":"10.1007","volume":"51","author":[{"given":"Johad","family":"Khoury","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Nassar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rimma","family":"Kramsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarek","family":"Saadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,13]]},"reference":[{"key":"293_CR1","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/MCG.0000000000000853","volume":"52","author":"T Saadi","year":"2018","unstructured":"Saadi T, Khoury J. Is there a relationship between treatment with direct antiviral agents for HCV infection and the development of malignancies? J Clin Gastroenterol. 2018;52:353\u20139.","journal-title":"J Clin Gastroenterol"},{"key":"293_CR2","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1517\/14656566.2015.1114099","volume":"16","author":"EY Cheng","year":"2015","unstructured":"Cheng EY, Saab S, Holt CD, Busuttil RW. Paritaprevir\/ritonavir\/ombitasvir and dasabuvir for the treatment of chronic hepatitis C virus infection. Expert Opin Pharmacother. 2015;16:2835\u201348.","journal-title":"Expert Opin Pharmacother"},{"key":"293_CR3","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.jhep.2013.11.009","volume":"60","author":"ZM Younossi","year":"2014","unstructured":"Younossi ZM, Singer ME, Mir HM, Henry L, Hunt S. Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients. J Hepatol. 2014;60:530\u20137.","journal-title":"J Hepatol"},{"key":"293_CR4","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/nrgastro.2010.100","volume":"7","author":"JD Yang","year":"2010","unstructured":"Yang JD, Roberts LR. Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol. 2010;7:448\u201358.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"293_CR5","doi-asserted-by":"publisher","first-page":"174","DOI":"10.7326\/0003-4819-131-3-199908030-00003","volume":"131","author":"H Yoshida","year":"1999","unstructured":"Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of hepatocarcinogenesis by interferon therapy. Ann Intern Med. 1999;131:174\u201381.","journal-title":"Ann Intern Med"},{"key":"293_CR6","doi-asserted-by":"publisher","first-page":"12896","DOI":"10.3748\/wjg.v21.i45.12896","volume":"21","author":"S Fiorino","year":"2015","unstructured":"Fiorino S, Bacchi-Reggiani L, de Biase D, Fornelli A, Masetti M, Tura A, et al. Possible association between hepatitis C virus and malignancies different from hepatocellular carcinoma: a systematic review. World J Gastroenterol. 2015;21:12896\u2013953.","journal-title":"World J Gastroenterol"},{"key":"293_CR7","doi-asserted-by":"publisher","first-page":"djw035","DOI":"10.1093\/jnci\/djw035","volume":"108","author":"P Mahale","year":"2016","unstructured":"Mahale P, Sturgis EM, Tweardy DJ, Ariza-Heredia EJ, Torres HA. Association between hepatitis C virus and head and neck cancers. J Natl Cancer Inst. 2016;108:djw035.","journal-title":"J Natl Cancer Inst"},{"key":"293_CR8","doi-asserted-by":"publisher","first-page":"107","DOI":"10.4254\/wjh.v8.i2.107","volume":"8","author":"G Pozzato","year":"2016","unstructured":"Pozzato G, Mazzaro C, Dal Maso L, et al. Hepatitis C virus and non-Hodgkin\u2019s lymphomas: meta-analysis of epidemiology data and therapy options. World J Hepatol. 2016;8:107\u201316.","journal-title":"World J Hepatol"},{"key":"293_CR9","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1097\/MCG.0000000000000892","volume":"51","author":"PJ Gaglio","year":"2017","unstructured":"Gaglio PJ. Extrahepatic and intrahepatic malignancies in patients with HCV who achieve an SVR with directly acting antiviral agents: should we be concerned that DAA therapy contributed to this phenomenon? J Clin Gastroenterol. 2017;51:657\u20138.","journal-title":"J Clin Gastroenterol"},{"key":"293_CR10","first-page":"1","volume":"68","author":"V Conteduca","year":"2014","unstructured":"Conteduca V, Sansonno D, Russi S, et al. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents. J Inf Secur. 2014;68:1\u201320.","journal-title":"J Inf Secur"},{"key":"293_CR11","doi-asserted-by":"publisher","first-page":"785","DOI":"10.4254\/wjh.v8.i19.785","volume":"8","author":"A Bonaventura","year":"2016","unstructured":"Bonaventura A, Montecucco F. Sofosbuvir\/velpatasvir: a promising combination. World J Hepatol. 2016;8:785\u20139.","journal-title":"World J Hepatol"},{"issue":"Suppl 1","key":"293_CR12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/liv.13027","volume":"36","author":"T Asselah","year":"2016","unstructured":"Asselah T, Boyer N, Saadoun D, Martinot-Peignoux M, Marcellin P. Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives. Liver Int. 2016;36(Suppl 1):47\u201357.","journal-title":"Liver Int"},{"key":"293_CR13","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.jhep.2016.06.015","volume":"65","author":"F Conti","year":"2016","unstructured":"Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol. 2016;65:727\u201333.","journal-title":"J Hepatol"},{"key":"293_CR14","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jhep.2016.04.008","volume":"65","author":"M Reig","year":"2016","unstructured":"Reig M, Marino Z, Perello C, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol. 2016;65:719\u201326.","journal-title":"J Hepatol"},{"key":"293_CR15","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.jhep.2016.05.045","volume":"65","author":"ANRS collaborative study group on hepatocellular carcinoma","year":"2016","unstructured":"ANRS collaborative study group on hepatocellular carcinoma. Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts. J Hepatol. 2016;65:734\u201340.","journal-title":"J Hepatol"},{"key":"293_CR16","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jhep.2015.03.025","volume":"63","author":"European Association for the Study of the Liver","year":"2015","unstructured":"European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015;63:199\u2013236.","journal-title":"J Hepatol"},{"key":"293_CR17","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/hep.27950","volume":"62","author":"AASLD\/IDSA HCV Guidance Panel","year":"2015","unstructured":"AASLD\/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62:932\u201354.","journal-title":"Hepatology"},{"key":"293_CR18","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jhep.2016.09.001","volume":"66","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol. 2017;66:153\u201394.","journal-title":"J Hepatol"},{"key":"293_CR19","doi-asserted-by":"publisher","first-page":"818","DOI":"10.7326\/M15-1000","volume":"163","author":"GT Everson","year":"2015","unstructured":"Everson GT, Towner WJ, Davis MN, Wyles DL, Nahass RG, Thuluvath PJ, et al. Sofosbuvir with velpatasvir in treatment-naive noncirrhotic patients with genotype 1 to 6 hepatitis C virus infection: a randomized trial. Ann Intern Med. 2015;163:818\u201326.","journal-title":"Ann Intern Med"},{"key":"293_CR20","doi-asserted-by":"publisher","first-page":"809","DOI":"10.7326\/M15-1014","volume":"163","author":"S Pianko","year":"2015","unstructured":"Pianko S, Flamm SL, Shiffman ML, Kumar S, Strasser SI, Dore GJ, et al. Sofosbuvir plus Velpatasvir combination therapy for treatment-experienced patients with genotype 1 or 3 hepatitis C virus infection: a randomized trial. Ann Intern Med. 2015;163:809\u201317.","journal-title":"Ann Intern Med"},{"key":"293_CR21","doi-asserted-by":"publisher","unstructured":"Ioannou GN, Green PK, Berry K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol. 2017;(17):32273\u20130. https:\/\/doi.org\/10.1016\/j.jhep.2017.08.030.","DOI":"10.1016\/j.jhep.2017.08.030"},{"key":"293_CR22","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/jvh.12843","volume":"25","author":"E Rodriguez de Santiago","year":"2018","unstructured":"Rodriguez de Santiago E, Velazquez Kennedy K, Garcia Gonzalez M, et al. HCV-positive lymphoma after sustained virological response with direct-acting antiviral agents: the game is not over after HCV eradication. J Viral Hepat. 2018;25:614\u20135.","journal-title":"J Viral Hepat"},{"key":"293_CR23","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1038\/bjc.2011.450","volume":"105","author":"A Smith","year":"2011","unstructured":"Smith A, Howell D, Patmore R, Jack A, Roman E. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer. 2011;105:1684\u201392.","journal-title":"Br J Cancer"},{"key":"293_CR24","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1002\/ijc.27711","volume":"132","author":"F Bray","year":"2013","unstructured":"Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 2013;132:1133\u201345.","journal-title":"Int J Cancer"},{"key":"293_CR25","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1097\/MEG.0b013e3283484795","volume":"23","author":"R Lambert","year":"2011","unstructured":"Lambert R, Sauvaget C, de Camargo Cancela M, Sankaranarayanan R. Epidemiology of cancer from the oral cavity and oropharynx. Eur J Gastroenterol Hepatol. 2011;23:633\u201341.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"293_CR26","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1093\/jnci\/djt292","volume":"105","author":"J Ma","year":"2013","unstructured":"Ma J, Siegel R, Jemal A. Pancreatic cancer death rates by race among US men and women, 1970-2009. J Natl Cancer Inst. 2013;105:1694\u2013700.","journal-title":"J Natl Cancer Inst"},{"key":"293_CR27","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/j.1442-2042.2008.02194.x","volume":"16","author":"S Hinotsu","year":"2009","unstructured":"Hinotsu S, Akaza H, Miki T, Fujimoto H, Shinohara N, Kikuchi E, et al. Bladder cancer develops 6 years earlier in current smokers: analysis of bladder cancer registry data collected by the cancer registration committee of the Japanese Urological Association. Int J Urol. 2009;16:64\u20139.","journal-title":"Int J Urol"},{"key":"293_CR28","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1002\/1097-0142(20000915)89:6<1291::AID-CNCR14>3.0.CO;2-O","volume":"89","author":"GC Alfsen","year":"2000","unstructured":"Alfsen GC, Thoresen SO, Kristensen GB, Skovlund E, Abeler VM. Histopathologic subtyping of cervical adenocarcinoma reveals increasing incidence rates of endometrioid tumors in all age groups: a population based study with review of all nonsquamous cervical carcinomas in Norway from 1966 to 1970, 1976 to 1980, and 1986 to 1990. Cancer. 2000;89:1291\u20139.","journal-title":"Cancer"},{"key":"293_CR29","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87\u2013108.","journal-title":"CA Cancer J Clin"},{"key":"293_CR30","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1111\/jvh.12746","volume":"24","author":"A Schiavinato","year":"2017","unstructured":"Schiavinato A, Zanetto A, Pantano G, Tosato F, Nabergoj M, Fogar P, et al. Polyclonal and monoclonal B lymphocytes response in HCV-infected patients treated with direct-acting antiviral agents. J Viral Hepat. 2017;24:1168\u201376.","journal-title":"J Viral Hepat"},{"issue":"3","key":"293_CR31","doi-asserted-by":"publisher","first-page":"197","DOI":"10.5114\/ceh.2018.78124","volume":"4","author":"A Pellicelli","year":"2018","unstructured":"Pellicelli A, Giannelli V, Zoli V, Pellicelli V, Zignego AL. Antiviral therapy in hepatitis C-infected patients prevents relapse of diffuse large B cell lymphoma. Clin Exp Hepatol. 2018 Sep;4(3):197\u2013200.","journal-title":"Clin Exp Hepatol"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-019-00293-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-019-00293-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-019-00293-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T12:41:20Z","timestamp":1628599280000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-019-00293-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,13]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["293"],"URL":"https:\/\/doi.org\/10.1007\/s12029-019-00293-y","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"value":"1941-6628","type":"print"},{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,13]]},"assertion":[{"value":"13 August 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the institutional review board (IRB).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}